Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
13 Jan 2017
Change (% chg)

$0.05 (+2.56%)
Prev Close
$1.95
Open
$1.90
Day's High
$2.00
Day's Low
$1.90
Volume
28,905
Avg. Vol
102,643
52-wk High
$4.36
52-wk Low
$1.55

BDSI.OQ

Chart for BDSI.OQ

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $108.24
Shares Outstanding(Mil.): 54.12
Dividend: --
Yield (%): --

Financials

  BDSI.OQ Industry Sector
P/E (TTM): -- 30.00 30.92
EPS (TTM): -0.77 -- --
ROI: -103.01 15.39 14.82
ROE: -562.17 16.57 16.24

BRIEF-Stonepine Capital Management reports a 6 pct passive stake in Biodelivery Sciences International as of Jan 3, 2017

* Stonepine Capital Management LLC reports a 6 percent passive stake in Biodelivery Sciences International Inc as of Jan 3, 2017 - SEC filing Source text: (http://bit.ly/2iR1ESL) Further company coverage:

Jan 13 2017

BRIEF-BioDelivery Sciences International closed on deals contemplated by termination agreement

* Biodelivery sciences international-closed on deals contemplated by termination agreement, dated dec. 7, 2016 by and between co, its units - sec filing Source text (http://bit.ly/2ian7Vz) Further company coverage:

Jan 09 2017

BRIEF-Biodelivery Sciences reports Q3 loss per share of $0.30

* Biodelivery Sciences International - Buprenorphine 30-day injection IND submission expected by year-end

Nov 09 2016

BRIEF-BioDelivery Sciences announces preferred formulary status for BUNAVAIL on Texas Medicaid

* BioDelivery Sciences announces preferred formulary status for BUNAVAIL on Texas Medicaid Source text for Eikon: Further company coverage:

Oct 24 2016

Cigna ends preauthorization requirement to treat opioid addiction

Health insurer Cigna Corp has discontinued its policy of requiring doctors to seek authorization before treating opioid addicts, as part of a fight against an epidemic of opioid abuse, New York Attorney General Eric Schneiderman said on Friday.

Oct 21 2016

UPDATE 2-Cigna ends preauthorization requirement to treat opioid addiction

Oct 21 Health insurer Cigna Corp has discontinued its policy of requiring doctors to seek authorization before treating opioid addicts, as part of a fight against an epidemic of opioid abuse, New York Attorney General Eric Schneiderman said on Friday.

Oct 21 2016

BRIEF-Biodelivery Sciences names Mark Sirgo as vice chairman

* Biodelivery sciences announces additions to its board of directors

Oct 05 2016

BRIEF-Biodelivery Sciences Q2 loss per share $0.31

* Biodelivery Sciences provides corporate update and reports second quarter 2016 financial results

Aug 09 2016

Earnings vs. Estimates